Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart

Trends in Endocrinology and Metabolism

Volumn 28, Issue 6, 2017, Pages 416-427

  Fu, Qin ^a   Wang, Qingtong ^b   Xiang, Yang K ^c,d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; PHOSPHODIESTERASE IV;

ADRENERGIC SYSTEM; CARDIAC MUSCLE; DESENSITIZATION; ENZYME PHOSPHORYLATION; HEART; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REPERFUSION; REVIEW; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; INSULIN; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 85014089561     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2017.02.002     Document Type: Review

References (93)

1. Contreras-Ferrat, A.E., An inositol 1,4,5-triphosphate (IP3)-IP3 receptor pathway is required for insulin-stimulated glucose transporter 4 translocation and glucose uptake in cardiomyocytes. Endocrinology 151 (2010), 4665–4677.
2. Mangmool, S., et al. beta-adrenergic receptor and insulin resistance in the heart. Biomol. Ther. 25 (2017), 44–56.
3. Shao, D., Tian, R., Glucose transporters in cardiac metabolism and hypertrophy. Compr. Physiol. 6 (2015), 331–351.
4. Ciccarelli, M., et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 123 (2011), 1953–1962.
5. Rane, S., et al. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell. Signal. 22 (2010), 1054–1062.
6. Fu, Q., et al. Insulin inhibits cardiac contractility by inducing a Gi-biased beta2-adrenergic signaling in hearts. Diabetes 63 (2014), 2676–2689.
7. Mandic, M., et al. Demonstration of a direct interaction between beta2-adrenergic receptor and insulin receptor by BRET and bioinformatics. PLoS One, 9, 2014, e112664.
8. Nestel, P.J., et al. Markers of sympathetic nervous system activity associate with complex plasma lipids in metabolic syndrome subjects. Atherosclerosis 256 (2016), 21–28.
9. Battiprolu, P.K., et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J. Clin. Invest. 122 (2012), 1109–1118.
10. Mangmool, S., et al. Sustained betaAR stimulation mediates cardiac insulin resistance in a PKA-dependent manner. Mol. Endocrinol. 30 (2016), 118–132.
11. Morisco, C., et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ. Res. 96 (2005), 180–188.
12. Inoue, T., et al. Hyperinsulinemia and sulfonylurea use are independently associated with left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus with suboptimal blood glucose control. BMJ Open Diabetes Res. Care, 4, 2016, e000223.
13. Zhu, Y., et al. Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation. Mol. Endocrinol. 27 (2013), 172–184.
14. Harmancey, R., et al. Chronic hyperinsulinemia causes selective insulin resistance and down-regulates uncoupling protein 3 (UCP3) through the activation of sterol regulatory element-binding protein (SREBP)-1 transcription factor in the mouse heart. J. Biol. Chem. 290 (2015), 30947–30961.
15. Shimizu, I., et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 15 (2012), 51–64.
16. Alves-Wagner, A.B., Beta-adrenergic blockade increases GLUT4 and improves glycemic control in insulin-treated diabetic Wistar rats. Auton. Neurosci. 193 (2015), 108–116.
17. Ayers, K., et al. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59 (2012), 893–898.
18. Uriel, N., et al. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur. J. Heart Fail. 13 (2011), 195–199.
19. Zhu, W., et al. Interaction of beta1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling. JCI Insight, 1, 2016, e84969.
20. Irannejad, R., et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature 495 (2013), 534–538.
21. Morisco, C., et al. Endocytosis machinery is required for beta1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes. Cardiovasc. Res. 78 (2008), 36–44.
22. Fu, Q., Xiang, Y.K., Trafficking of beta-adrenergic receptors: implications in intracellular receptor signaling. Prog. Mol. Biol. Transl. Sci. 132 (2015), 151–188.
23. Nikolaev, V.O., et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327 (2010), 1653–1657.
24. Barbagallo, F., et al. Genetically encoded biosensors reveal PKA hyperphosphorylation on the myofilaments in rabbit heart failure. Circ. Res. 119 (2016), 931–943.
25. Xiang, Y.K., Compartmentalization of beta-adrenergic signals in cardiomyocytes. Circ. Res. 109 (2011), 231–244.
26. Wu, M.P., et al. Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of beta2-AR/PI3K/AKT signaling pathway. Pharmacol. Res. 104 (2016), 115–123.
27. Woo, A.Y., et al. Biased beta2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br. J. Pharmacol. 172 (2015), 5444–5456.
28. Echouffo-Tcheugui, J.B., Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from get with the guidelines-heart failure registry. Am. Heart J. 182 (2016), 9–20.
29. Lorenzo, C., et al. Novel protein glycan-derived markers of systemic inflammation and C-reactive protein in relation to glycemia, insulin resistance, and insulin secretion. Diabetes Care, 2016, 10.2337/dc16-1569 Published online December 28, 2016.
30. Okonko, D.O., Shah, A.M., Heart failure: mitochondrial dysfunction and oxidative stress in CHF. Nat. Rev. Cardiol. 12 (2015), 6–8.
31. Boly, C.A., et al. The effect of perioperative insulin treatment on cardiodepression in mild adiposity in mice. Cardiovasc. Diabetol., 15, 2016, 135.
32. Fu, Q., et al. Insulin induces IRS2-dependent and GRK2-mediated beta2AR internalization to attenuate betaAR signaling in cardiomyocytes. Cell. Signal. 27 (2015), 707–715.
33. Wang, Q., et al. Inhibiting insulin-mediated beta2AR activation prevents diabetes-associated cardiac dysfunction. Circulation 135 (2016), 73–88.
34. Fu, Q., et al. High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β2-adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts. J. Physiol., 2016, 10.1113/JP273314 Published online.
35. Llano-Diez, M., et al. The role of reactive oxygen species in beta-adrenergic signaling in cardiomyocytes from mice with the metabolic syndrome. PLoS One, 11, 2016, e0167090.
36. Wilson, G.A., et al. beta-adrenergic responsiveness in the type 2 diabetic heart: effects on cardiac reserve. Med. Sci. Sports Exerc., 2016, 10.1249/MSS.0000000000001184 Published online December 14, 2016.
37. Fu, Q., et al. A long lasting beta1 adrenergic receptor stimulation of cAMP/protein kinase A (PKA) signal in cardiac myocytes. J. Biol. Chem. 289 (2014), 14771–14781.
38. Zhao, C.Y., et al. Interaction between phosphodiesterases in the regulation of the cardiac beta-adrenergic pathway. J. Mol. Cell Cardiol. 88 (2015), 29–38.
39. Pantalone, K.M., et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes. Metab. 14 (2012), 803–809.
40. Straznicky, N.E., et al. Comparable attenuation of sympathetic nervous system activity in obese subjects with normal glucose tolerance, impaired glucose tolerance, and treatment naive type 2 diabetes following equivalent weight loss. Front. Physiol., 7, 2016, 516.
41. Holmager, P., et al. Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. BMC Cardiovasc. Disord., 17, 2017, 22.
42. Utrera-Lagunas, M., Abnormal myocardial perfusion and risk of heart failure in patients with type 2 diabetes mellitus. Exp. Clin. Cardiol. 18 (2013), e44–e46.
43. Kishi, S., et al. Association of insulin resistance and glycemic metabolic abnormalities with LV structure and function in middle age: the CARDIA study. JACC Cardiovasc. Imaging, 2016, 10.1016/j.jcmg.2016.02.033 Published online August 11, 2016.
44. Kamal, F.A., et al. Taking the heart failure battle inside the cell: small molecule targeting of Gbetagamma subunits. J. Mol. Cell. Cardiol. 51 (2011), 462–467.
45. Sato, P.Y., et al. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol. Rev. 95 (2015), 377–404.
46. Casey, L.M., et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ. Res. 107 (2010), 532–539.
47. Thal, D.M., et al. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem. Biol. 7 (2012), 1830–1839.
48. Schumacher, S.M., et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci. Transl. Med., 7, 2015, 277ra31.
49. Horinouchi, T., et al. Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells. Br. J. Pharmacol. 173 (2016), 1018–1032.
50. Lucas, E., et al. Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. Cardiovasc. Diabetol., 15, 2016, 155.
51. Rengo, G., et al. Impact of diabetes mellitus on lymphocyte GRK2 protein levels in patients with heart failure. Eur. J. Clin. Invest. 45 (2015), 187–195.
52. Lucas, E., et al. Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. Biochim. Biophys. Acta 1842:12 Pt A (2014), 2448–2456.
53. Vila-Bedmar, R., et al. Reversal of diet-induced obesity and insulin resistance by inducible genetic ablation of GRK2. Sci. Signal., 8, 2015, ra73.
54. Ciccarelli, M., et al. GRK2 at the control shaft of cellular metabolism. Curr. Pharm. Des. 18 (2012), 121–127.
55. Shimizu, I., et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 120 (2010), 1506–1514.
56. Riehle, C., et al. Insulin receptor substrates are essential for the bioenergetic and hypertrophic response of the heart to exercise training. Mol. Cell. Biol. 34 (2014), 3450–3460.
57. Maillet, M., et al. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 14 (2013), 38–48.
58. van Dijk, C.G., et al. Distinct endothelial cell responses in the heart and kidney microvasculature characterize the progression of heart failure with preserved ejection fraction in the obese ZSF1 rat with cardiorenal metabolic syndrome. Circ. Heart Fail., 9, 2016, e002760.
59. Peng, X., et al. PPARgamma-PI3K/AKT-NO signal pathway is involved in cardiomyocyte hypertrophy induced by high glucose and insulin. J. Diabetes Complications 29 (2015), 755–760.
60. Chowdhury, D., et al. Prohibitin confers cytoprotection against ISO-induced hypertrophy in H9c2 cells via attenuation of oxidative stress and modulation of Akt/Gsk-3beta signaling. Mol. Cell. Biochem. 425 (2017), 155–168.
61. Yang, B., et al. TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner. Am. J. Transl. Res. 8 (2016), 3848–3860.
62. Mei, L., et al. Increased cardiac remodeling in cardiac-specific Flt-1 receptor knockout mice with pressure overload. Cell Tissue Res. 362 (2015), 389–398.
63. Vidal, M., et al. beta-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gbetagamma/Erk-dependent pathway. Cardiovasc. Res. 96 (2012), 255–264.
64. Bhavsar, P.K., et al. Clenbuterol induces cardiac myocyte hypertrophy via paracrine signalling and fibroblast-derived IGF-1. J. Cardiovasc. Transl. Res. 3 (2010), 688–695.
65. Murray, D.R., et al. beta2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo. J. Mol. Cell Cardiol. 52 (2012), 206–218.
66. Koitabashi, N., Kass, D.A., Reverse remodeling in heart failure?mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 9 (2011), 147–157.
67. Ramalingam, L., et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochim. Biophys. Acta, 2016, 10.1016/j.bbadis.2016.07.019 Published online August 4, 2016.
68. Muniyappa, R., Yavuz, S., Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol. Cell Endocrinol. 378 (2013), 59–69.
69. Huang, J.P., et al. High-fructose and high-fat feeding correspondingly lead to the development of lysoPC-associated apoptotic cardiomyopathy and adrenergic signaling-related cardiac hypertrophy. Int. J Cardiol. 215 (2016), 65–76.
70. Pagano, F., et al. Beta2-adrenergic signaling affects the phenotype of human cardiac progenitor cells through EMT modulation. Pharmacol. Res., 2017, 10.1016/j.phrs.2017.01.016 Published online January 7, 2017.
71. Xu, S., et al. CaMKII induces permeability transition through Drp1 phosphorylation during chronic beta-AR stimulation. Nat. Commun., 7, 2016, 13189.
72. Ambrose, L.J., et al. Investigating mitochondrial metabolism in contracting HL-1 cardiomyocytes following hypoxia and pharmacological HIF activation identifies HIF-dependent and independent mechanisms of regulation. J. Cardiovasc. Pharmacol. Ther. 19 (2014), 574–585.
73. Bovo, E., et al. Increased energy demand during adrenergic receptor stimulation contributes to Ca(2+) wave generation. Biophys. J. 109 (2015), 1583–1591.
74. Landis, J., Shaw, L.M., Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3beta to regulate aerobic glycolysis. J. Biol. Chem. 289 (2014), 18603–18613.
75. Kelsall, I.R., et al. R3F, a novel membrane-associated glycogen targeting subunit of protein phosphatase 1 regulates glycogen synthase in astrocytoma cells in response to glucose and extracellular signals. J. Neurochem. 118 (2011), 596–610.
76. Chandramouli, C., et al. Myocardial glycogen dynamics: new perspectives on disease mechanisms. Clin. Exp. Pharmacol. Physiol. 42 (2015), 415–425.
77. Martin, S.D., et al. Mitochondrial dysfunction has divergent, cell type-dependent effects on insulin action. Mol. Metab. 3 (2014), 408–418.
78. Ji, L., et al. The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts. Can. J. Physiol. Pharmacol. 94 (2016), 996–1006.
79. Manna, P., et al. Vitamin D supplementation inhibits oxidative stress and upregulate SIRT1/AMPK/GLUT4 cascade in high glucose-treated 3T3L1 adipocytes and in adipose tissue of high fat diet-fed diabetic mice. Arch. Biochem. Biophys. 615 (2017), 22–34.
80. Ma, L., et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am. J. Physiol. Heart Circ. Physiol. 302 (2012), H2341–H2351.
81. Xue, H., et al. Rutaecarpine and evodiamine selected as beta1-AR inhibitor candidates using beta1-AR/CMC-offline-UPLC/MS prevent cardiac ischemia-reperfusion injury via energy modulation. J. Pharm. Biomed. Anal. 115 (2015), 307–314.
82. Park, K.M., et al. Carvedilol-responsive microRNAs, miR-199a-3p and -214 protect cardiomyocytes from simulated ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 311 (2016), H371–H383.
83. Huang, M.H., et al. Therapeutic synergy and complementarity for ischemia/reperfusion injury: beta1-adrenergic blockade and phosphodiesterase-3 inhibition. Int. J. Cardiol. 214 (2016), 374–380.
84. Zhang, Q., et al. Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats. Br. J. Pharmacol. 160 (2010), 1561–1572.
85. Fajardo, G., et al. beta2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways. J. Mol. Cell Cardiol. 51 (2011), 781–789.
86. Carr 3rd, R., et al. beta-arrestin-biased signaling through the beta2-adrenergic receptor promotes cardiomyocyte contraction. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E4107–E4116.
87. Bhushan, S., et al. Selective beta2-adrenoreceptor stimulation attenuates myocardial cell death and preserves cardiac function after ischemia-reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 1865–1874.
88. Liepinsh, E., et al. The heart is better protected against myocardial infarction in the fed state compared to the fasted state. Metabolism 63 (2014), 127–136.
89. Ji, L., et al. Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitrative stress. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E871–E880.
90. Salie, R., et al. High carbohydrate and high fat diets protect the heart against ischaemia/reperfusion injury. Cardiovasc. Diabetol., 13, 2014, 109.
91. Straus, S., et al. Glucosa-insulin-potassium (GIK) solution used with diabetic patients provides better recovery after coronary bypass operations. Med. Arch. 67 (2013), 84–87.
92. Ellis, K.L., et al. Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial. Pharmacogenomics, 2016, 10.1038/tpj.2015.84 Published online December 9, 2016.
93. Riehle, C., Abel, E.D., Insulin signaling and heart failure. Circulation Res. 118 (2016), 1151–1169.